Company news

Passage Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

August 4, 2022

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

August 3, 2022

Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

July 27, 2022

Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors

July 5, 2022

Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

June 8, 2022

Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

June 7, 2022

Passage Bio Announces Leadership Transition

May 31, 2022

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2022

Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting

May 17, 2022

Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights

May 15, 2022

Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022

May 8, 2022

Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

May 1, 2022

Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

March 28, 2022

Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway

March 14, 2022

Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition

March 9, 2022

Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

March 2, 2022

Passage Bio to Participate in Upcoming March Investor Conferences

February 28, 2022

Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

February 23, 2022

Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium

February 10, 2022

Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11

January 30, 2022

Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline

January 9, 2022

Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

December 16, 2021

Passage Bio Announces Pipeline Expansion and Clinical Program Update

December 7, 2021

Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

November 18, 2021

Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights

November 3, 2021

Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021

October 27, 2021

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

September 6, 2021

Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights

August 4, 2021

Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.

August 3, 2021

Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

July 28, 2021

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2021

Passage Bio Announces Key Executive Appointments

July 18, 2021

Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio

May 31, 2021

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

May 10, 2021

Passage Bio to Host Virtual R&D Event on May 17

May 9, 2021

Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights

May 4, 2021

Passage Bio Partners with InformedDNA® to Offer Genetic Counseling and Testing for Patients with Frontotemporal Dementia (FTD), a Form of Early Onset Dementia

May 2, 2021

Passage Bio to Report First Quarter 2021 Financial Results on May 5, 2021

April 28, 2021

Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease

April 4, 2021

Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis

March 31, 2021

Passage Bio Appoints Eliseo O. Salinas, M.D., MSc, as Chief Research & Development Officer

March 21, 2021

Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

March 2, 2021

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

February 18, 2021

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options

February 7, 2021

Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations

January 27, 2021

Passage Bio Announces Pricing of Public Offering

January 20, 2021

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25

January 18, 2021

Passage Bio Announces Launch of Proposed Public Offering

January 18, 2021

Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021

January 10, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 39 decks. Every deck is listed under its year.